

Claims

WHAT IS CLAIMED IS:

1. - 12. (canceled)
13. (new) A phospholipid gel comprising a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second phospholipid is a negatively charged phospholipid.
14. (new) The phospholipid gel according to claim 13, wherein the first and second phospholipids are of natural origin, semi-synthetic origin, or synthetic origin.
15. (new) The phospholipid gel according to claim 13, wherein the first and second phospholipids are selected from di(C₈-C₂₂ acyl) phosphatidyl choline and di(C₈-C₂₂ acyl) phosphatidyl glycerol.
16. (new) The phospholipid gel according to claim 15, wherein the first and second phospholipids are dipalmitoyl phosphatidyl choline and dipalmitoyl phosphatidyl glycerol.
17. (new) The phospholipid gel according to claim 13, wherein a total phospholipid concentration is within a range of 6-40 % by weight.
18. (new) The phospholipid gel according to claim 15, wherein the phosphatidyl choline and the phosphatidyl glycerol are present in a ratio within a range of 10:1 to 10:0.25.
19. (new) The phospholipid gel according to claim 13 containing a pharmacologically active substance.
20. (new) The phospholipid gel according to claim 19, wherein the pharmacologically active substance is a steroid; a non-steroidal antiphlogistic agent; an antibiotic; an antioxidant; or an antiepileptic agent.
21. (new) The phospholipid gel according to claim 20, wherein the steroid is selected from the group consisting of cholesterol, hydrocortisone, and dexamethasone.
22. (new) The phospholipid gel according to claim 20, wherein the non-steroidal antiphlogistic agent is selected from the group consisting of ibuprofen, diclofenac, flurbiprofen, and nabumetone.

23. (new) The phospholipid gel according to claim 20, wherein the antibiotic is selected from the group consisting of tetracycline, a derivative of tetracycline, an aminoglycoside, a macrolid antibiotic, a nitroimidazole derivative, an antibiotic peptide, and an antibiotic oligonucleotide.

24. (new) The phospholipid gel according to claim 23, wherein the aminoglycoside is gentamycine or neomycine; wherein the macrolid antibiotic is erythromycine; and wherein the nitroimidazole derivative is metronidazole or flucidic acid.

25. (new) The phospholipid gel according to claim 20, wherein the antioxidant is selected from the group consisting of vitamin E and coenzyme Q₁₀.

26. (new) The phospholipid gel according to claim 20, wherein the antiepileptic agent is selected from the group consisting of valproic acid and salts of valproic acid.

27. (new) The phospholipid gel according to claim 13 produced by shaking, vortexing, mixing by a stirrer, extrusion, or homogenization.

28. (new) A method for moisturizing or calming normal or diseased skin or mucous membrane, the method comprising the step applying a substance containing the phospholipid gel according to claim 13.

29. (new) A method of preparing medicaments or cosmetic substances for treating the skin, mucous membrane, natural or surgically generated body cavities or body compartments accessible by local or parenteral application, the method comprising the step of providing the phospholipid gel according to claim 13 as a carrier.

30. (new) A method of stabilizing a solution, wherein the method comprises the step of adding the phospholipid gel according to claim 13 to the solution for solubilizing hardly soluble substances and/or preventing precipitation.